Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Is It The End For OncoGenex? Custirsen Fails In Second Phase III Prostate Cancer Trial

Executive Summary

Custirsen, the lead drug candidate from OncoGenex, failed in a second Phase III clinical trial – a trial that may have represented the company's last, best hope of success.

Advertisement

Related Content

Deal Watch: Taking Care Of Business Before J.P. Morgan
Does CheckMate 026 Take Bristol Out Of The End Game?
Early Tecentriq OK Gives Roche/Genentech Jump On PD-L1 Bladder Cancer Market
Teva bails from OncoGenex custirsen deal; paying $27m
OncoGenex sinks, sees prostate potential after custirsen failure

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097137

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel